Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ADK | P55263 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19385329 | 1.00 | POLB (0.33) | POLBADKACACBMAPK14PRMT6 | |
| SCHEMBL19397142 | 0.87 | HTT (0.34) | POLBADKACACBHTTRET | |
| SCHEMBL19379673 | 0.80 | LMNA (0.37) | — | |
| SCHEMBL19379663 | 0.80 | LMNA (0.37) | — | |
| SCHEMBL19379669 | 0.79 | HTT (0.31) | HTT | |
| SCHEMBL19379655 | 0.79 | HTT (0.31) | HTT | |
| SCHEMBL31228231 | 0.79 | ADK (0.36) | POLBADKPRMT6HTTPRMT5 | |
| SCHEMBL19397144 | 0.76 | ADK (0.38) | ADKRETKDRPRMT5WDR77 | |
| SCHEMBL30745131 | 0.76 | ADK (0.38) | ADKRETKDRPRMT5WDR77 | |
| SCHEMBL19379658 | 0.76 | ADK (0.38) | ADKRETKDRPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4292658-A2 | ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS | Novartis AG (CH) | 2023-12-20 | — | — | EP | disclosed |
| EP-3433257-B1 | ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS | NOVARTIS AG (CH) | 2023-10-11 | — | — | EP | disclosed |
| US-10428105-B2 | Alkynyl nucleoside analogs as inhibitors of human rhinovirus | NOVARTIS AG (CH) | 2019-10-01 | — | — | US | disclosed |
| US-20180258129-A1 | ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS | NOVARTIS AG (CH) | 2018-09-13 | — | — | US | disclosed |
| US-9988416-B2 | Alkynyl nucleoside analogs as inhibitors of human rhinovirus | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
| US-20170275329-A1 | ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS | NOVARTIS INSTITUTE FOR TROPICAL DISEASES PTE LTD (SG) | 2017-09-28 | — | — | US | disclosed |
| US-20170275329-A1 | ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS | NOVARTIS INSTITUTE FOR TROPICAL DISEASES PTE LTD (SG) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275329-A1 | ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS | RNASEH1, ENTPD5, SARNP | POLB 968/4885ADK 578/4885ACACB 4274/4885 |
| US-20180258129-A1 | ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS | RNASEH1, ENTPD5, SARNP | POLB 968/4885ADK 578/4885ACACB 4274/4885 |
| US-10428105-B2 | Alkynyl nucleoside analogs as inhibitors of human rhinovirus | RNASEH1, ENTPD5, SARNP | POLB 968/4885ADK 578/4885ACACB 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.